Sign inCreate account

Report workspace

Add to folder
NCT01842308COMPLETEDanonymous

A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)

Sponsor

Source record

Mayo Clinic

Phase

Source record

Phase 1/2

Modality

AI-normalized

small molecule

Target

AI-normalized

Carfilzomib targets the proteasome, inhibiting its function and thereby blocking the degradation of pro-apoptotic factors, leading to apoptosis in cancer cells. Melphalan acts as an alkylating agent, damaging DNA and preventing cell division.

Indication / condition

AI-normalized

DS Stage I Plasma Cell Myeloma

Intervention

Source record

Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carfilzomib, Laboratory Biomarker Analysis, Melphalan

Source & freshness

Source record

NCT ID

NCT01842308

Original source

ClinicalTrials.gov

Source last updated

Sep 01, 2020

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01842308

Title

A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)

Sponsor

Mayo Clinic

Status

COMPLETED

Phase

Phase 1/2

Condition raw

DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Condition normalized

DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Carfilzomib targets the proteasome, inhibiting its function and thereby blocking the degradation of pro-apoptotic factors, leading to apoptosis in cancer cells. Melphalan acts as an alkylating agent, damaging DNA and preventing cell division.

Target normalized

Carfilzomib targets the proteasome, inhibiting its function and thereby blocking the degradation of pro-apoptotic factors, leading to apoptosis in cancer cells. Melphalan acts as an alkylating agent, damaging DNA and preventing cell division.

Interventions

Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carfilzomib, Laboratory Biomarker Analysis, Melphalan

Public preview

Source record

The CARAMEL trial, sponsored by Mayo Clinic, investigates the combination of carfilzomib and melphalan as a conditioning regimen prior to autologous stem cell transplantation in multiple myeloma patients. Given the increasing prevalence of multiple myeloma and the need for effective pre-transplant therapies, this combination could position itself as a significant treatment option in a competitive market. The trial's completion and subsequent results may enhance the commercial viability of carfilzomib, particularly in combination therapies, and could influence future treatment guidelines. Stakeholders should monitor the outcomes closely for potential licensing or partnership opportunities.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT01842308

Status

COMPLETED

Phase

Phase 1/2

Sponsor

Mayo Clinic

Executive brief

Investment-Ready Snapshot

The CARAMEL trial, sponsored by Mayo Clinic, investigates the combination of carfilzomib and melphalan as a conditioning regimen prior to autologous stem cell transplantation in multiple myeloma patients. Given the increasing prevalence of multiple myeloma and the need for effective pre-transplant therapies, this combination could position itself as a significant treatment option in a competitive market. The trial's completion and subsequent results may enhance the commercial viability of carfilzomib, particularly in combination therapies, and could influence future treatment guidelines. Stakeholders should monitor the outcomes closely for potential licensing or partnership opportunities.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 01, 2020
Internal syncJun 16, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01842308

Indication

DS Stage I Plasma Cell Myeloma

Modality

small molecule

Target

Carfilzomib targets the proteasome, inhibiting its function and thereby blocking the degradation of pro-apoptotic factors, leading to apoptosis in cancer cells. Melphalan acts as an alkylating agent, damaging DNA and preventing cell division.

Intervention

Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carfilzomib, Laboratory Biomarker Analysis, Melphalan

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.